Discovery of PACAP and its receptors in the brain

Pituitary adenylate-cyclase-activating polypeptide (PACAP) is a 27- or 38-amino acid neuropeptide, which belongs to the vasoactive intestinal polypeptide (VIP)/glucagon/secretin family. PACAP shows particularly high homology (~ 68%) to VIP. Because of the high homology of the amino acid sequences of PACAP and VIP, these peptides share three class B-G-protein coupled receptors: the PAC1-Receptor (PAC1-R), the VPAC1-Receptor (VPAC1-R) and VPAC2-Receptor (VPAC2-R). These receptors have high homology to each other, and their high homology is utilized for these discoveries. This review provides mainly an overview of the history of the discovery of PACAP and its three receptors.

• Publication year

  2018

• Venue

  The Journal of Headache and Pain

• Publication date

  2018-04-04

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1186/s10194-018-0855-1PMID 29619773PMCID 5884755
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pituitary adenylate cyclase‐activating polypeptide promotes eccrine gland sweat secretion

  2017cited by this paper
• PACAP suppresses dry eye signs by stimulating tear secretion

  2016cited by this paper
• Pleiotropic and retinoprotective functions of PACAP

  2016cited by this paper
• PACAP as a neuroprotective factor in ischemic neuronal injuries.

  2015cited by this paper
• PACAP38 Suppresses Cortical Damage in Mice with Traumatic Brain Injury by Enhancing Antioxidant Activity

  2014cited by this paper
• Duplications of the Neuropeptide Receptor VIPR2 Confer Significant Risk for Schizophrenia

  2011cited by this paper
• Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for schizophrenia

  2011cited by this paper
• Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor

  2011cited by this paper
• Possible association between the pituitary adenylate cyclase-activating polypeptide (PACAP) gene and major depressive disorder.

  2010cited by this paper
• Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors: 20 Years after the Discovery

  2009cited by this paper
• Pituitary adenylate cyclase-activating polypeptide is associated with schizophrenia

  2007cited by this paper
• Localization and characterization of pituitary adenylate cyclase‐activating polypeptide receptors in the human cerebellum during development

  2006cited by this paper
• Inhibition of Self‐Renewal and Induction of Neural Differentiation by PACAP in Neural Progenitor Cells

  2006cited by this paper
• The pituitary adenylate cyclase-activating polypeptide is a physiological inhibitor of platelet activation.

  2004cited by this paper
• VIP and PACAP induce selective neuronal differentiation of mouse embryonic stem cells

  2004cited by this paper
• Possible involvement of a cyclic AMP-dependent mechanism in PACAP-induced proliferation and ERK activation in astrocytes.

  2003cited by this paper
• Altered psychomotor behaviors in mice lacking pituitary adenylate cyclase-activating polypeptide (PACAP)

  2001cited by this paper
• Targeted disruption of the pituitary adenylate cyclase-activating polypeptide gene results in early postnatal death associated with dysfunction of lipid and carbohydrate metabolism.

  2001cited by this paper
• The action of pituitary adenylate cyclase activating polypeptide (PACAP) on passive avoidance learning. The role of transmitters.

  2000cited by this paper
• Mild deficits in mice lacking pituitary adenylate cyclase-activating polypeptide receptor type 1 (PAC1) performing on memory tasks.

  2000cited by this paper
• Prohormone Convertases 1 and 2 Process ProPACAP and Generate Matured, Bioactive PACAP38 and PACAP27 in Transfected Rat Pituitary GH4C1 Cells

  1999cited by this paper
• Circadian changes in PACAP type 1 (PAC1) receptor mRNA in the rat suprachiasmatic and supraoptic nuclei.

  1998cited by this paper
• Testis-specific prohormone convertase PC4 processes the precursor of pituitary adenylate cyclase-activating polypeptide (PACAP).

  1998cited by this paper
• Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems.

  1998cited by this paper
• Autoradiographic Visualization of the Receptor Subclasses for Vasoactive Intestinal Polypeptide (VIP) in Rat Brain

  1998cited by this paper
• International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide.

  1998influential reference
• Localization and gene expression of the receptor for pituitary adenylate cyclase-activating polypeptide in the rat brain.

  1997cited by this paper
• Distribution of the mRNA for a pituitary adenylate cyclase‐activating polypeptide receptor in the rat brain: An in situ hybridization study

  1996cited by this paper
• Effects of pituitary adenylate cyclase-activating polypeptide (PACAP) on gonadotropin-releasing hormone and somatostatin gene expression in the rat brain.

  1996cited by this paper
• Pituitary adenylate cyclase activating polypeptide prevents apoptosis in cultured cerebellar granule neurons.

  1996cited by this paper
• Localization of Pituitary Adenylate Cyclase‐Activating Polypeptide and Its Type I Receptors in the Rat Ovary: Immunohistochemistry and in Situ Hybridization a

  1996cited by this paper
• Pituitary adenylate cyclase-activating polypeptide acts within the medial basal hypothalamus to inhibit prolactin and luteinizing hormone secretion.

  1996cited by this paper
• Prevention of ischemia-induced death of hippocampal neurons by pituitary adenylate cyclase activating polypeptide.

  1996cited by this paper
• Cyclic AMP and pituitary adenylate cyclase-activating polypeptide (PACAP) prevent programmed cell death of cultured rat cerebellar granule cells.

  1996cited by this paper
• PACAP type I receptor gene expression in the paraventricular and supraoptic nuclei of rats

  1996cited by this paper
• Differential expression of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes in clonal pituitary somatotrophs and gonadotrophs.

  1995cited by this paper
• Concentrations of pituitary adenylate cyclase activating polypeptide (PACAP) in human brain nuclei.

  1995cited by this paper
• The distribution of vasoactive intestinal peptide2 receptor messenger RNA in the rat brain and pituitary gland as assessed by in situ hybridization.

  1995cited by this paper
• Dipsogenic effect of pituitary adenylate cyclase activating polypeptide (PACAP38) injected into the lateral hypothalamus.

  1995cited by this paper
• Cloning and functional characterization of the human vasoactive intestinal peptide (VIP)-2 receptor.

  1995cited by this paper
• Pituitary adenylate cyclase-activating polypeptide stimulates arginine vasopressin release in conscious rats

  1994cited by this paper
• Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions.

  1994cited by this paper
• Molecular cloning and functional characterization of a human VIP receptor from SUP-T1 lymphoblasts.

  1994cited by this paper
• Cloning and functional characterization of a third pituitary adenylate cyclase-activating polypeptide receptor subtype expressed in insulin-secreting cells.

  1994cited by this paper
• Properties of the VIP-PACAP type II receptor stably expressed in CHO cells.

  1994cited by this paper
• Molecular cloning and expression of a cDNA encoding a receptor for pituitary adenylate cyclase activating polypeptide (PACAP)

  1993cited by this paper
• Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor.

  1993cited by this paper
• Molecular cloning and functional expression of a cDNA encoding a human pituitary adenylate cyclase activating polypeptide receptor.

  1993cited by this paper
• Molecular cloning and functional expression of the pituitary adenylate cyclase-activating polypeptide type I receptor.

  1993cited by this paper
• Pituitary adenylate cyclase-activating polypeptide stimulates arginine vasopressin release in conscious rats.

  1993cited by this paper
• Molecular cloning and functional expression of rat cDNAs encoding the receptor for pituitary adenylate cyclase activating polypeptide (PACAP).

  1993cited by this paper
• Molecular cloning and tissue distribution of a receptor for pituitary adenylate cyclase-activating polypeptide.

  1993cited by this paper
• Distribution, molecular characterization of pituitary adenylate cyclase-activating polypeptide and its precursor encoding messenger RNA in human and rat tissues.

  1993cited by this paper
• Localization and characterization of PACAP receptors in the rat cerebellum during development: evidence for a stimulatory effect of PACAP on immature cerebellar granule cells.

  1993cited by this paper
• The VIP2 receptor: Molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide

  1993cited by this paper
• Binding sites for pituitary adenylate cyclase activating polypeptide (PACAP): comparison with vasoactive intestinal polypeptide (VIP) binding site localization in rat brain sections.

  1992cited by this paper
• Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide.

  1992influential reference
• Pituitary adenylate cyclase activating polypeptide (PACAP) reduces food intake in mice

  1992cited by this paper
• Investigation of the interaction of VIP binding sites with VIP and PACAP in human brain.

  1992cited by this paper
• Structure of the human pituitary adenylate cyclase activating polypeptide (PACAP) gene.

  1992cited by this paper
• Molecular cloning and expression of a cDNA encoding the secretin receptor.

  1991cited by this paper
• Properties and distribution of receptors for pituitary adenylate cyclase activating peptide (PACAP) in rat brain and spinal cord.

  1991influential reference
• Tissue distribution of PACAP as determined by RIA: highly abundant in the rat brain and testes.

  1991cited by this paper
• [125I]vasoactive intestinal polypeptide binding sites: quantitative autoradiographic distribution in the rat spinal cord.

  1991cited by this paper
• Autoradiographic distribution of pituitary adenylate cyclase activating polypeptide (PACAP) binding sites in the rat brain.

  1991cited by this paper
• A novel peptide which stimulates adenylate cyclase: molecular cloning and characterization of the ovine and human cDNAs.

  1990cited by this paper
• The novel VIP-like hypothalamic polypeptide PACAP interacts with high affinity receptors in the human neuroblastoma cell line NB-OK.

  1990cited by this paper
• Characterization and distribution of binding sites for the hypothalamic peptide, pituitary adenylate cyclase-activating polypeptide.

  1990cited by this paper
• Binding sites of a novel neuropeptide pituitary-adenylate-cyclase-activating polypeptide in the rat brain and lung.

  1990cited by this paper
• Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38).

  1990cited by this paper
• Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells.

  1989cited by this paper
• Autoradiographic mapping of [mono[125I]iodo-Tyr10, MetO17]vasoactive intestinal peptide binding sites in the rat brain.

  1987cited by this paper
• Characterization and autoradiographic distribution of vasoactive intestinal peptide binding sites in the rat central nervous system.

  1986cited by this paper
• In vitro autoradiographic localization of vasoactive intestinal peptide (VIP) binding sites in the rat central nervous system.

  1984cited by this paper
• Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly.

  1982cited by this paper
• Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin.

  1982cited by this paper

• Novel small-molecule positive allosteric modulator 1 with blood-brain barrier penetration activity exerts anti-cellular senescence effects via the PAC1-R/YY1/SIRT6 pathway

  2026cites this paper
• A chemogenetic approach for temporal and cell-specific activation of endogenous GPCRs in vivo.

  2026cites this paper
• Regulation of behavioral responses to single prolonged stress in male and female rats: Role of PACAP

  2025cites this paper
• Where are we now? Biased signalling of Class B G protein-coupled receptor-targeted therapeutics.

  2025cites this paper
• Decoding migraine disorders: parathyroid hormone-related peptide receptors as key genetic drivers

  2025cites this paper
• The role and interaction of hypothalamic-related neurotransmitters in migraine

  2025cites this paper
• VPAC1 and VPAC2 Receptor Heterozygosity Confers Distinct Biological Properties to BV2 Microglial Cells

  2025cites this paper
• Neuronal PAC1 deletion impairs structural plasticity.

  2025cites this paper
• Protective effects of PACAP against high glucose-induced inflammation on air-liquid interface corneal epithelium barrier.

  2025cites this paper
• Decoding PACAP signaling: Splice variants, pathways and designer drugs

  2025cites this paper
• Entangled cellular and molecular relationships at the sensory neuron-cancer interface.

  2025cites this paper
• PAC1 Receptor Knockout Mice Reveal Critical Links Between ER Stress, Myelin Homeostasis, and Neurodegeneration

  2025cites this paper
• PACAP versus CGRP in migraine: From mouse models to clinical translation

  2025cites this paper
• PACAP‐38 in Cluster Headache: A Prospective, Case–Control Study of a Potential Treatment Target

  2025cites this paper
• PACAP Signalling Network in the Nucleus Accumbens Core Regulates Reinstatement Behaviour in Rat

  2025cites this paper
• Sex difference in vasoactive intestinal polypeptide neural projection in the limbic system of the mouse brain.

  2025cites this paper
• Temporal dynamics of immune response following a single-dose PACAP administration in Pacific white shrimp Litopenaeus vannamei

  2025cites this paper
• The hypothalamic effects of PACAP on the hypothalamic-pituitary-gonadal axis in male mice

  2025cites this paper
• Temporal Effects of a Viral Peptide on Glucose-Stimulated Insulin Secretion.

  2025cites this paper
• Activation of central Angiotensin-(1-7)/Mas receptor alleviates synaptic damage in diabetes-associated cognitive impairment via modulating AKT/FOXO1/PACAP axis

  2025cites this paper
• Tripterygium glycoside tablets and triptolide alleviate experimental autoimmune encephalomyelitis mice involving the PACAP/cAMP signaling pathway.

  2025cites this paper
• Targeting PACAP: Beyond Migraine to Cluster, Menstrual, and Post-traumatic Headaches

  2025cites this paper
• Discovery of Feeding Regulatory Peptides and The Importance of Peptide Discovery Research.

  2025cites this paper
• Pituitary adenylyl cyclase-activating polypeptide modulates the stress response: the involvement of different brain areas and microglia

  2025cites this paper
• Comparing the impact of systemic pituitary adenylate-cyclase-activating polypeptide (PACAP) and calcitonin gene-related peptide (CGRP) on motion-induced nausea and balance behaviors in mice

  2025cites this paper
• PACAP sequence modifications modulate the peptide antimicrobial activity against bacterial pathogens affecting aquaculture.

  2024cites this paper
• Antimicrobial neuropeptides and their therapeutic potential in vertebrate brain infectious disease

  2024cites this paper
• Anxiety and the brain: Neuropeptides as emerging factors.

  2024cites this paper
• From circadian sleep disruption to Neuroprotection: The potential of VIP/PACAP in Alzheimer’s disease treatment

  2024cites this paper
• Differential Expression of PACAP/VIP Receptors in the Post-Mortem CNS White Matter of Multiple Sclerosis Donors

  2024cites this paper
• Exploring the Role of Neuropeptide PACAP in Cytoskeletal Function Using Spectroscopic Methods

  2024cites this paper
• Hippocampal PACAP signaling activation triggers a rapid antidepressant response

  2024cites this paper
• PACAP ameliorates obesity‐induced insulin resistance through FAIM/Rictor/AKT axis

  2024cites this paper
• Same same, but different: exploring the enigmatic role of the pituitary adenylate cyclase-activating polypeptide (PACAP) in invertebrate physiology

  2024cites this paper
• Investigating the potential role of the pituitary adenylate cyclase-activating polypeptide (PACAP) in regulating the ubiquitin signaling pathway in poultry.

  2024cites this paper
• A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Bioactive Peptides.

  2024cites this paper
• Understanding the Biological Relationship between Migraine and Depression

  2024cites this paper
• Emerging and future directions of migraine research and treatment.

  2024cites this paper
• The Healthy and Diseased Retina Seen through Neuron–Glia Interactions

  2024cites this paper
• Biochemical aspects of migraine pathogenesis

  2024cites this paper
• From CGRP to PACAP, VIP, and Beyond: Unraveling the Next Chapters in Migraine Treatment

  2023cites this paper
• Dynamic, sex‐ and diet‐specific pleiotropism in the PAC1 receptor‐mediated regulation of arcuate proopiomelanocortin and Neuropeptide Y/Agouti related peptide neuronal excitability by anorexigenic ventromedial nucleus PACAP neurons

  2023cites this paper
• Unveiling adcyap1 as a protective factor linking pain and nerve regeneration through single-cell RNA sequencing of rat dorsal root ganglion neurons

  2023cites this paper
• Development of a New Enzyme-Linked Immunosorbent Assay (ELISA) for Measuring the Content of PACAP in Mammalian Tissue and Plasma

  2023cites this paper
• The effect of PACAP administration on LPS-induced cytokine expression in the Atlantic salmon SHK-1 cell line.

  2023cites this paper
• Emerging experimental drugs in clinical trials for migraine: observations and key talking points

  2023influential citation
• Early Alterations of PACAP and VIP Expression in the Female Rat Brain Following Spinal Cord Injury

  2023cites this paper
• Exosome-sheathed ROS-responsive nanogel to improve targeted therapy in perimenopausal depression

  2023cites this paper
• Crosstalk between the neuroendocrine system and bone homeostasis.

  2023cites this paper
• Neural Progenitor Cells and the Hypothalamus

  2023cites this paper
• Altered Hippocampal and Striatal Expression of Endothelial Markers and VIP/PACAP Neuropeptides in a Mouse Model of Systemic Lupus Erythematosus

  2023cites this paper
• Future targets for migraine treatment beyond CGRP

  2023cites this paper
• PACAP key interactions with PAC1, VPAC1, and VPAC2 identified by molecular dynamics simulations

  2023cites this paper
• Multi-omics integration analysis of GPCRs in pan-cancer to uncover inter-omics relationships and potential driver genes

  2023cites this paper
• Activation of the PACAP/PAC1 Signaling Pathway Accelerates the Repair of Impaired Spatial Memory Caused by an Ultradian Light Cycle

  2023influential citation
• Increased pituitary adenylate cyclase-activating peptide genes expression in the prefrontal cortex in schizophrenia in relation to suicide

  2023cites this paper
• Impact of Ovariectomy on the Anterior Pituitary Gland in Female Rats

  2023influential citation
• Young adult and aged female rats are vulnerable to amygdala-dependent, but not hippocampus-dependent, memory impairment following short-term high-fat diet.

  2023cites this paper
• PACAP inhibition alleviates neuropathic pain by modulating Nav1.7 through the MAPK/ERK signaling pathway in a rat model of chronic constriction injury.

  2023cites this paper
• Brain‐derived neurotrophic factor (BDNF) induces antagonistic action to Nogo signaling by the upregulation of lateral olfactory tract usher substance (LOTUS) expression

  2022cites this paper
• Potential Therapeutic Role of Pituitary Adenylate Cyclase-Activating Polypeptide for Dry Eye Disease

  2022influential citation
• Targeting the neurological comorbidities of multiple sclerosis: the beneficial effects of VIP and PACAP neuropeptides.

  2022influential citation
• Signal Transduction by VIP and PACAP Receptors

  2022cites this paper
• PACAP and VIP Mitigate Rotenone-Induced Inflammation in BV-2 Microglial Cells

  2022influential citation
• Regulatory Roles of Antimicrobial Peptides in the Nervous System: Implications for Neuronal Aging

  2022cites this paper
• The Role of Pituitary Adenylate Cyclase-Activating Polypeptide and Vasoactive Intestinal Peptide in Migraine Pathogenesis

  2022cites this paper
• PACAP/GCGa Is an Important Modulator of the Amphioxus CNS-Hatschek’s Pit Axis, the Homolog of the Vertebrate Hypothalamic-Pituitary Axis in the Basal Chordates

  2022cites this paper
• Regulation of alcohol drinking by ventral striatum and extended amygdala circuitry.

  2022cites this paper
• Exploring the Pro-Phagocytic and Anti-Inflammatory Functions of PACAP and VIP in Microglia: Implications for Multiple Sclerosis

  2022cites this paper
• The PACAP Paradox: Dynamic and Surprisingly Pleiotropic Actions in the Central Regulation of Energy Homeostasis

  2022cites this paper
• Targeting VIP and PACAP Receptor Signaling: New Insights into Designing Drugs for the PACAP Subfamily of Receptors

  2022influential citation
• Parasites and the neuroendocrine control of fish intestinal function: an ancient struggle between pathogens and host

  2022cites this paper
• Immunomodulatory Role of Neuropeptides in the Cornea

  2022cites this paper
• The Effects of Patchouli Alcohol on Diarrhea-Predominant Irritable Bowel Syndrome are Correlated with Phenotypic Plasticity in Myenteric Neurons and the Targeted Regulation of Myosin Va.

  2022cites this paper
• Neuroprotective Effects of gH625-lipoPACAP in an In Vitro Fluid Dynamic Model of Parkinson’s Disease

  2022cites this paper
• Localization of the neuropeptides pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal peptide, and their receptors in the basal brain blood vessels and trigeminal ganglion of the mouse CNS; an immunohistochemical study

  2022cites this paper
• Understanding VPAC receptor family peptide binding and selectivity

  2022cites this paper
• The neuropeptide PACAP alleviates T. gondii infection-induced neuroinflammation and neuronal impairment

  2022cites this paper
• Intranasal Peptide Therapeutics: A Promising Avenue for Overcoming the Challenges of Traditional CNS Drug Development

  2022cites this paper
• Role of PACAP in migraine: An alternative to CGRP?

  2022cites this paper
• Hedgehog signaling in endocrine and folliculo-stellate cells of the adult pituitary

  2021cites this paper
• Parkinson disease: protective role and function of neuropeptides.

  2021cites this paper
• Vascular effects of neuropeptides and UDP-β-S and alterations after stroke

  2021cites this paper
• The PACAP/PAC1 Receptor System and Feeding

  2021cites this paper
• Lipopeptide Pepducins as Therapeutic Agents.

  2021cites this paper
• The Role of Neuropeptides in Pathogenesis of Dry Dye

  2021cites this paper
• An ancient neuropeptide defends the brain against infection

  2021cites this paper
• Correlation of Decreased Serum Pituitary Adenylate Cyclase-Activating Polypeptide and Vasoactive Intestinal Peptide Levels With Non-motor Symptoms in Patients With Parkinson’s Disease

  2021cites this paper
• Chronic Migraine Pathophysiology and Treatment: A Review of Current Perspectives

  2021cites this paper
• Molecular Mechanism for PACAP 38-Induced Neurite Outgrowth in PC12 Cells

  2021cites this paper
• The Prominent Role of Pituitary Adenylate Cyclase-Activating Polypeptide in Spermatogenesis and Function of Spermatozoa: A Mini Review

  2021cites this paper
• PAC1 receptor–mediated clearance of tau in postsynaptic compartments attenuates tau pathology in mouse brain

  2021cites this paper
• PACAP and PAC1 Receptor Expression in Human Insulinomas

  2021cites this paper
• Phospholipids stabilize binding of pituitary adenylate cyclase-activating peptide to vasoactive intestinal polypeptide receptor

  2021cites this paper
• Endogenous Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Plays a Protective Effect Against Noise-Induced Hearing Loss

  2021cites this paper
• Inhibition of PACAP/PAC1/VPAC2 signaling impairs the consolidation of social recognition memory and nitric oxide prevents this deficit.

  2021cites this paper
• Activation of the VPAC2 Receptor Impairs Axon Outgrowth and Decreases Dendritic Arborization in Mouse Cortical Neurons by a PKA-Dependent Mechanism

  2020cites this paper
• Pituitary Adenylate Cyclase-Activating Polypeptide: A Promising Neuroprotective Peptide in Stroke

  2020cites this paper
• GIP receptor suppresses PAC1receptor‐mediated neuronal differentiation via formation of a receptor heterocomplex

  2020cites this paper
• Targeting pituitary adenylate cyclase-activating polypeptide (PACAP) with monoclonal antibodies in migraine prevention: a brief review

  2020influential citation